Azacitidine
Philadelphia Chromosome
The First Affiliated Hospital of Soochow UniversitySmall moleculePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
34 Active assets in the Philadelphia Chromosome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nilotinib The University of Hong Kong | Phase 2 | BBB |
Blinatumomab Novartis Pharmaceuticals | Phase 3 | BBB |
Cytosin-Arabinosid Novartis Pharmaceuticals | Phase 3 | BBB |
METHOTREXATE Novartis Pharmaceuticals | Phase 3 | BB |
Imatinib The University of Hong Kong | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Azacitidine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
73 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →